Stanley-Laman Group’s Edwards Lifesciences EW Stock Holding History

Stanley-Laman Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-68,771	Closed	-$6.27M	–	249
2020 Q4	$6.27M	Sell	68,771 -190	-0.3%	-$15.8K	1.11%	28
2020 Q3	$5.5M	Sell	68,961 -1,946	-3%	-$152K	1.21%	25
2020 Q2	$4.9M	Buy	70,907 +728	+1%	+$51.7K	1.18%	26
2020 Q1	$4.41M	Buy	70,179 +67,296	+2,334%	+$4.85M	1.34%	18
2019 Q4	$224K	Sell	2,883 -819	-22%	-$64K	0.05%	261
2019 Q3	$271K	Sell	3,702 -702	-16%	-$49.3K	0.07%	226
2019 Q2	$271K	Buy	+4,404	New	+$266K	0.07%	235
2017 Q1	–	Sell	-12,000	Closed	-$375K	–	252
2016 Q4	$375K	Hold	12,000	–	–	0.12%	200
2016 Q3	$482K	Hold	12,000	–	–	0.2%	142
2016 Q2	$399K	Hold	12,000	–	–	0.16%	168
2016 Q1	$353K	Hold	12,000	–	–	0.07%	194
2015 Q4	$316K	Hold	12,000	–	–	0.05%	263
2015 Q3	$284K	Hold	12,000	–	–	0.06%	254
2015 Q2	$285K	Hold	12,000	–	–	0.05%	248
2015 Q1	$285K	Hold	12,000	–	–	0.05%	253
2014 Q4	$255K	Hold	12,000	–	–	0.05%	271
2014 Q3	$204K	Buy	+12,000	New	+$189K	0.04%	272

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Stanley-Laman Group's EW Position: Q1 2021 in Review

Stanley-Laman Group sold out of Edwards Lifesciences (EW) in Q1 2021, closing a stake of 68,771 shares — an estimated $6.27M sold.

Stanley-Laman Group first reported a position in EW in Q3 2014 and held it in 17 quarters. The position peaked at $6.27M in Q4 2020. 1,143 funds tracked by Wall St. Rank hold EW as of Q1 2021.

Stanley-Laman Group reported no remaining Edwards Lifesciences position as of Q1 2021 after selling out during the quarter.
Stanley-Laman Group sold 68,771 Edwards Lifesciences shares in Q1 2021, an estimated $6.27M.
Stanley-Laman Group first reported a position in Edwards Lifesciences in Q3 2014 and held it in 17 quarters.
Stanley-Laman Group's Edwards Lifesciences position peaked at $6.27M in Q4 2020.
1,143 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Stanley-Laman Group's 13F filing for Q1 2021, filed 5 May 2021.